A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)
This is a phase 2/3, global, multicenter, open-label, multi-cohort study designed to evaluate the safety and efficacy of targeted therapies or immunotherapy as single agents or in combination in participants with unresectable, advanced or metastatic NSCLC determined to harbor oncogenic somatic mutations or positive by tumor mutational burden (TMB) assay as identified by a blood-based next-generation sequencing (NGS) circulating tumor DNA (ctDNA) assay.
Ask AI to explain this studyKey things to know
This describes the study’s primary purpose.
Plus 10 other study approaches.
These are broad labels—not an eligibility decision.
Checked against the public recordLast updated Sep 3, 2026 · Source: ClinicalTrials.gov
The study is underway but is not accepting new participants.
Interventional
Locations may change over time.
Study sponsor
What this study is about
- Purpose
- Treatment
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Sponsor
- Hoffmann-La Roche
- Interventions being studied
- Drug: Alectinib; Drug: Atezolizumab; Drug: Pemetrexed; Drug: Cisplatin; Drug: Carboplatin; Drug: Gemcitabine; Drug: Entrectinib; Drug: Cobimetinib; Drug: Vemurafenib; Drug: Bevacizumab; Drug: Divarasib; Drug: Docetaxel
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.
- Histologically or cytologically confirmed diagnosis of unresectable Stage IIIb not amenable to treatment with combined modality chemoradiation (advanced) or Stage IV (metastatic) NSCLC
- Eastern Cooperative Oncology Group (ECOG) Performance Status 0-2
- Measurable disease
- Adequate recovery from most recent systemic or local treatment for cancer
- Adequate organ function
- Life expectancy greater than or equal to (\>/=) 12 weeks
- For female participants of childbearing potential and male participants, willingness to use acceptable methods of contraception
- Inability to swallow oral medication
- Women who are pregnant or lactating
- Symptomatic, untreated CNS metastases
- History of malignancy other than NSCLC within 5 years prior to screening with the exception of malignancies with negligible risk of metastasis or death
- Significant cardiovascular disease, such as New York Heart Association cardiac disease (Class II or greater), myocardial infarction, or cerebrovascular accident within 3 months prior to randomization, unstable arrhythmias, or unstable angina
- Known active or uncontrolled human immunodeficiency virus (HIV) infection
- Either a concurrent condition or history of a prior condition that places the patient at unacceptable risk if he/she were treated with the study drug or confounds the ability to interpret data from the study
- Inability to comply with other requirements of the protocol
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- UC DavisSacramento, California
- Rocky Mountain Cancer CenterDenver, Colorado
- SCRI Florida Cancer Specialists SouthFort Myers, Florida
- Florida Cancer Specialist, North RegionSt. Petersburg, Florida
- University of KentuckyLexington, Kentucky
- Comprehensive Cancer Centers of NevadaLas Vegas, Nevada
- Dartmouth Hitchcock Medical CenterLebanon, New Hampshire
- Weill Cornell Medical College-New York Presbyterian HospitalNew York, New York
- Montefiore Medical CenterThe Bronx, New York
- Oregon HSUPortland, Oregon
- St. Luke's University Health networkBethlehem, Pennsylvania
- Sarah Cannon Research Institute / Tennessee OncologyChattanooga, Tennessee
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Sep 3, 2026. Always confirm current availability with the study team.